Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05763459 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
A Phase 1 study, sponsored by Calico Life Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05763459 is a Phase 1 study that has completed, run by Calico Life Sciences. The registered enrollment target is 12 participants.
The verdict
NCT05763459, a Phase 1 study, has completed, sponsored by Calico Life Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
Interventions
- DRUG ABBV-CLS-7262
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2023-06-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05763459
The ClinicalTrials.gov registry entry for NCT05763459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calico Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABBV-CLS-7262 is the first listed.
NCT05763459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05763459 about?
NCT05763459 is a clinical study titled "A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects". This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
What is the current status of trial NCT05763459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-03-24. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT05763459?
The interventions under investigation include: ABBV-CLS-7262 (DRUG).
Who is sponsoring clinical trial NCT05763459?
This trial is sponsored by Calico Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.